Duodenal Jejunal Bypass Liner (DJBL) for treatment of type 2 diabetes and obesity: the risk benefit ratio from the worldwide EndoBarrier (EB) registry in 871 patients

被引：0

作者：

Laubner, K. ^{[1
]}

Seufert, J. ^{[1
]}

Aberle, J. ^{[2
]}

Frydenberg, H. ^{[3
]}

Munro, L. ^{[3
]}

Fishman, S. ^{[4
]}

Cohen, R. ^{[5
]}

Holtmann, G. ^{[6
]}

de Jonge, C. ^{[7
]}

Greve, J. ^{[7
]}

Kow, L. ^{[8
]}

Bessell, J. ^{[9
]}

Sourij, H. ^{[10
]}

Benes, M.

Ryder, R. E. J. ^{[11
]}

机构：

[1] Freiburg Univ, Freiburg, Germany

[2] Hamburg Univ, Hamburg, Germany

[3] Epworth Med Fdn, Richmond, Australia

[4] Sourasky Med, Tel Aviv, Israel

[5] Oswaldo Cruz Hosp, Sao Paulo, Brazil

[6] Princess Alexandra Hosp, Woolloongabba, Qld, Australia

[7] MUMC, Maastricht, Netherlands

[8] ABC, Adelaide, SA, Australia

[9] AOS, Adelaide, SA, Australia

[10] Med Univ, Graz, Austria

[11] City Hosp, Birmingham, W Midlands, England

来源：

DIABETOLOGIA | 2019年 / 62卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

803

引用

页码：S390 / S390

页数：1

共 50 条

[1] Duodenal jejunal bypass liner (DJBL) for treatment of type 2 diabetes and obesity: risks and benefits among 926 patients in the worldwide EndoBarrier (EB) registry
Ryder, R. E. J.
Sen Gupta, P.
Stengel, R.
Mitchell, K.
Drummond, R.
Frydenberg, H.
Munro, L.
Fishman, S.
Cohen, R.
de Jonge, C.
Greve, J.
Benes, M.
Aberle, J.
Laubner, K.
Seufert, J.
DIABETOLOGIA, 2021, 64 (SUPPL 1) : 298 - 298
[2] Duodenal jejunal bypass liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic andCVDrisk factor improvements vs risks in patients treated worldwide
Ryder, R. E. J.
Sen Gupta, P.
Battelino, T.
Kotnik, P.
Teare, J.
Ruban, A.
Frydenberg, H.
Munro, L.
Fishman, S.
Cohen, R.
de Jonge, C.
Greve, J. -W.
Sourij, H.
Laubner, K.
Seufert, J.
DIABETOLOGIA, 2022, 65 (SUPPL 1) : S29 - S30
[3] Impact of duodenal-jejunal bypass liner (DJBL) on NAFLD in patients with obesity and type 2 diabetes mellitus
Roehlen, Natascha
Laubner, Katharina
Nicolaus, Leonard
Schwacha, Henning
Bettinger, Dominik
Krebs, Andreas
Thimme, Robert
Seufert, Jochen
NUTRITION, 2022, 103-104
[4] Duodenal Jejunal Bypass Liner (DJBL) treatment for type 2 diabetes and obesity: glycaemic and CVD risk factor improvements vs risks among 1068 patients treated worldwide
Ryder, R. E. J.
Stein, J.
Battelino, T.
Teare, J.
Ruban, A.
Frydenberg, H.
Munro, L.
Fishman, S.
Cohen, R.
de Jonge, C.
Greve, J-W
Sourij, H.
Sen Gupta, P.
Laubner, K.
Seufert, J.
DIABETOLOGIA, 2023, 66 (SUPPL 1) : S370 - S370
[5] Endoscopic Duodenal-Jejunal Bypass Liner (EndoBarrier®) for the treatment of type 2 diabetes mellitus
Laubner, K.
Perakakis, N.
Potasso, L.
Schwacha, H.
Seufert, J.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
[6] Safety- and efficacy-outcomes of the duodenal-jejunal bypass liner (DJBL) registry in obese patients with type 2 diabetes
Sauer, N.
Aberle, J.
Lautenbach, A.
Seufert, J.
Laubner, K.
DIABETOLOGIA, 2016, 59 : S39 - S40
[7] The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes
Patel, Shaneel R. H.
Hakim, David
Mason, John
Hakim, Nadey
SURGERY FOR OBESITY AND RELATED DISEASES, 2013, 9 (03) : 482 - 484
[8] Duodenal jejunal bypass liner treatment for type 2 diabetes and obesity: comparison between 9 and 12 months implantation using data from a worldwide registry
Ryder, R. E. J.
Lopez-Gonzalez, R.
Lazzara, C.
Gebelli, J. P.
Munro, L.
Frydenberg, H.
Stein, J.
Battelino, T.
Fishman, S.
Byrne, J.
de Jonge, C.
Greve, J. -W.
Cohen, R.
Yadagiri, M.
Sen Gupta, P.
DIABETOLOGIA, 2024, 67 : S379 - S379
[9] ENDOBARRIER DUODENO-JEJUNAL BYPASS LINER (ENDOSCOPIC TREATMENT OF TYPE II DIABETES AND OBESITY)
Frydenberg, Harry
OBESITY SURGERY, 2013, 23 (06) : 829 - 829
[10] The Duodenal–Jejunal Bypass Liner for the Treatment of Type 2 Diabetes Mellitus and/or Obesity: a Systematic Review
Ingrid Zechmeister-Koss
Mirjana Huić
Stefan Fischer
Obesity Surgery, 2014, 24 : 310 - 323

← 1 2 3 4 5 →